views
The viral vaccines market plays a crucial role in global public health, offering protection against a wide array of infectious diseases—such as influenza, measles, HPV, hepatitis, and emerging viral threats. Offerings include preventive and therapeutic vaccines, available in various formulations like liquid and lyophilized, and packaged in vials or prefilled syringes. Growth is driven by rising incidence of viral infections, strengthened government immunization programs, and innovations in vaccine platforms including viral vector, mRNA, and subunit vaccines. Advanced adjuvants and more stable formulations enhance efficacy and delivery options. As access expands and multivalent vaccines emerge, this market is expected to maintain steady global expansion over the coming years.
According to Fortune Business Insights, the global viral vaccines market was valued at USD 94.95 billion in 2022 and is projected to grow from USD 52.42 billion in 2023 to USD 70.99 billion by 2030, exhibiting a CAGR of 4.4% during the forecast period (2023–2030). In 2022, Asia Pacific dominated the viral vaccines market with a market share of 29.08%.
📌 Top Companies in the Market
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- SEQIRUS (CSL Limited) (Australia)
- Moderna, Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Services, Inc. (U.S.)
- Novavax (U.S.)
- Dynavax Technologies (U.S.)
Key Industry Development
In July 2023, GSK plc received UK MHRA authorization for its RSV vaccine, Arexvy, marking a milestone in the prevention of respiratory viral diseases .
Market Drivers
- Rising viral disease prevalence: Common viral infections (e.g. influenza, RSV), chronic viral illnesses (e.g. HIV, hepatitis B/C), and emerging threats (e.g. Ebola, Zika) continue to drive vaccine demand .
- Government immunization programs: Initiatives like the Global Polio Eradication Initiative (370 million children annually) and renewed focus on pandemic preparedness boost vaccine adoption .
- COVID-19 vaccine momentum: The pandemic accelerated vaccine development and manufacturing—surge in R&D, capacity, and regulatory pathways—all continue to benefit viral vaccine pipelines .
Market Restraints
- Pricing controls: Government-mandated price limits (e.g. Japan), along with post-pandemic pricing realignments (e.g. Pfizer COVID‑19 vaccine), may inhibit profitability .
- Cost of manufacturing: Complex requirements for cold-chain logistics, biosafety facilities, and sterile production environments raise barriers to entry .
Segmentation Analysis
By Form
Liquid vaccines led the market in 2022, favored for lower production costs and simple formulation. While lyophilized vaccines—more stable and shelf-friendly—are gaining prominence due to improved cold chain resilience .
By Container Format
Vials currently hold the largest share, driven by cost advantages. However, prefilled syringes (PFS) show fastest growth due to reduced dosing errors and better patient safety. Novavax began PFS production for Omicron-specific COVID vaccine in 2022 .
By Biosafety Level
Biosafety Level 3 vaccines—such as COVID-19—dominated in 2022 thanks to massive global immunization efforts . Level 2 vaccines (e.g. influenza, MMR, rotavirus) are also witnessing strong growth. Levels 1 and 4 hold smaller, niche shares .
Regional Insights
Asia Pacific (29.08% share in 2022)
Dominates the market at USD 27.62 billion, supported by high burden of hepatitis, SARS, COVID, HPV, and government programs. For instance, Japan’s USD 4.3 million grant for oral polio vaccines in 2021 .
North America
Second-largest. Robust vaccination drives—e.g. Ottawa’s 2022 flu campaign—and well-equipped regulatory systems support growth. The U.S. market is forecast to reach USD 26.14 billion by 2030 .
Europe
Strong market due to high R&D activity and government spending. Vaccine uptake—including booster and COVID programs—remains high even in vaccine‑hesitant countries .
Rest of World (Latin America, MEA)
Lower market penetration due to supply constraints and limited manufacturers. Initiatives like COVAX helped regions like Iraq receive 336,000 AstraZeneca doses in March 2021 .
Competitive Landscape
The market is concentrated with global leaders—Pfizer (Comirnaty), Moderna (Spikevax), and Merck driving sales. Sanofi, GSK, AstraZeneca, Johnson & Johnson, Seqirus, Novavax, and Dynavax are actively diversifying product pipelines .
Emerging Trends
- Shift to Prefilled Syringes: Demand rises for PFS for safer dosing and reduced waste .
- Stability-Enhancing Lyophilization: Advances in freeze-drying promote broader distribution in developing markets .
- Focus on Pandemic Preparedness: Post-COVID infrastructure—like CEPI—expanding pipeline for dengue, Ebola, RSV, and future threats.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/viral-vaccines-market-107531
Future Outlook & Opportunities
The viral vaccines market presents multiple growth avenues:
- Next-gen platforms: mRNA, viral vectors, and protein subunits across influenza, RSV, Zika, and HIV will drive innovation.
- Expanded immunization campaigns: Ongoing government initiatives for polio, HPV, Ebola, and COVID boosters.
- Emerging-market expansion: Investments in Asia-Pacific and Latin America will increase swing toward preventive care.
As production capacity stabilizes and price frameworks evolve, vaccine manufacturers must navigate regulation, logistics, and supply-chain optimization to sustainably scale.
Conclusion
The global viral vaccines market is resilient and evolving. Estimated to reach USD 70.99 billion by 2030, it is propelled by disease burden, technological breakthroughs, and immunization infrastructure . With strong growth expected across Asia-Pacific, North America, and Europe, companies are poised to benefit from higher adoption of liquid formulations, PFS delivery systems, and biosafety innovations—ushering in a new era of preventive healthcare.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
